- Methodology article
- Open Access
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators
© Zanella et al; licensee BioMed Central Ltd. 2009
Received: 16 October 2008
Accepted: 25 February 2009
Published: 25 February 2009
Independent luciferase reporter assays and fluorescent translocation assays have been successfully used in drug discovery for several molecular targets. We developed U2transLUC, an assay system in which luciferase and fluorescent read-outs can be multiplexed to provide a powerful cell-based high content screening method.
The U2transLUC system is based on a stable cell line expressing a GFP-tagged FOXO transcription factor and a luciferase reporter gene under the control of human FOXO-responsive enhancers. The U2transLUC assay measures nuclear-cytoplasmic FOXO shuttling and FOXO-driven transcription, providing a means to analyze these two key features of FOXO regulation in the same experiment. We challenged the U2transLUC system with chemical probes with known biological activities and we were able to identify compounds with translocation and/or transactivation capacity.
Combining different biological read-outs in a single cell line offers significant advantages over conventional cell-based assays. The U2transLUC assay facilitates the maintenance and monitoring of homogeneous FOXO transcription factor expression and allows the reporter gene activity measured to be normalized with respect to cell viability. U2transLUC is suitable for high throughput screening and can identify small molecules that interfere with FOXO signaling at different levels.
Forkhead box O (FOXO) proteins are emerging as transcriptional integrators of pathways that regulate a variety of cellular processes, including differentiation, metabolism, stress response, cell cycle and apoptosis [1–3]. FOXO transcription factors have been proposed to act as bona fide tumor suppressors due to their inhibitory effects on cell cycle and survival , properties mediated by their binding as monomers to consensus DNA binding sites. Their transcriptional activity is governed by a network of signaling events, the best recognized of which is the phosphorylation of FOXO proteins at three highly conserved serine and threonine residues by Akt that provokes its association with 14-3-3 protein and in turn, the nuclear exclusion of phospho-FOXO. However, the relocation of FOXO from the nucleus to the cytoplasm alone cannot account for the inhibitory effect of PI3K/Akt signaling on FOXO activity since a nuclear form of FOXO1 in which the nuclear export sequence is disrupted is still inhibited by the PI3K/Akt pathway . Indeed, the introduction of a negative charge in the positively charged DNA binding domain by means of FOXO phosphorylation at the second of the three Akt consensus sites inhibits DNA binding of FOXO [6, 7]. The FOXO DNA interaction is also regulated by the transfer of acetyl groups to lysine residues in FOXO proteins by the histone acetyltransferases (HATs) CBP and p300 , which alters the DNA binding capacity of FOXO1 and FOXO3a . Conversely, Sirt1 deacetylases deacetylate FOXO factors and regulate their DNA binding at specific target genes. Taken together, these observations suggest that translocation and transactivation are different and separate means to regulate FOXO. However, large scale tools are not available to assess the different levels of FOXO regulation. Therefore systematic chemical genetic or loss of function studies to investigate the complex regulation of FOXO factors have been limited only to certain aspects .
In anticancer drug discovery, much effort is directed towards identifying small molecule inhibitors of PI3K/Akt signaling using cell based high content screening. In particular, monitoring the intracellular localization of FOXO transcription factors has been used to screen large numbers of small molecules [10, 11]. Despite being commonly used as a reporter-gene system in drug discovery, luciferase-based transcriptional assays have not been applied to massive compound screens for PI3K/Akt inhibitors. Inhibiting the PI3K/Akt pathway causes FOXO3a to remain in the cell nucleus and subsequently, it induces the transcription of downstream genes. To take advantage of these regulatory features we generated the stable U2transLUC dual assay cell line that expresses FOXO responsive luciferase activity and GFP labelled FOXO. Thus, U2transLUC can be used to simultaneously monitor the intracellular translocation and the transcriptional activity of FOXO proteins. We have used this cell line in an attempt to identify small molecules that interfere with FOXO signaling.
Generation and testing of luciferase reporter gene constructs
In order to evaluate the responsiveness of the reporter constructs to the inhibition of the PI3K/Akt pathway, we transiently co-transfected the pGL-3xDBE or pGL-6xDBE construct with FOXO3a into U2OS cells and then treated them with the PI3K inhibitor, LY294002 (20 μM). Inhibition of the PI3K pathway increased FOXO-dependent transcription from both the pGL-3xDBE and pGL-6xDBE constructs approximately 3-fold (Figure 1B). By contrast, activation of the PI3K/Akt signaling pathway following exposure to insulin decreased this luciferase activity. However, the differences between the transcriptional activity of FOXO3a in untreated and insulin treated U2OS cells were small, indicating that steady-state level of PI3K/Akt activity was already quite high. In addition, to confirm the specificity of our system we examined the effect of constitutive FOXO activation by co-expressing the pGL-3xDBE or pGL-6xDBE reporter construct with FOXO3a-A3, a constitutively active form of FOXO3a in which the three PI3K-dependent phosphorylation sites have been mutated to alanine. The expression of FOXO3a-A3 induced a strong increase in pGL-3xDBE or pGL-6xDBE driven luciferase activity. Together, these data indicate that the firefly luciferase-based read-out of FOXO activity is very specific, and that it provides a large window to measure any upregulation in the response (e.g. upon the inhibition of the PI3K/Akt pathway). Since the responsiveness of the triple tandem repeat of DBE (pGL-3xDBE) to PI3K inhibition was slightly higher than that of pGL-6xDBE, the p3xDBE-luc construct was used to generate the stable cell assay line, U2transLUC.
Generation of the assay cell line, U2transLUC
The use of GFP fusion protein for normalization
Multiplexed U2transLUC assay
Discussion and conclusion
FOXO transcription factors are tightly regulated at different levels, including their intracellular translocation and transcriptional activity [1, 3]. Here we report the generation of a multiplexed assay system that is capable of simultaneously monitoring these signaling events. The assay system is based on U2transLUC cells that stably express two different reporter constructs. The intracellular translocation of FOXO factors is followed using a fluorescent tagged FOXO reporter protein, whereas transcriptional activity is monitored via FOXO-dependent luciferase production. We show here that the fluorescent and luminescent read-outs are compatible in the same cell.
The design of the U2transLUC screen presented here offers some major advantages over more classical cellular assays. Primary and secondary screens of small molecule compounds are usually performed in different cell systems. By contrast, the U2transLUC provides the possibility of using two different read-outs within the same experiment, enabling a direct comparison of the hits from each of these. These hits might be divided into translocation, transactivation and dual hits, and they may in turn be analyzed according to a corresponding hit ranking. The U2transLUC assay does not need the introduction of additional plasmids and hence, it avoids the limitations associated with transfection procedures.
The use of the GFP-FOXO fusion protein provides a multifunctional tool that allows for versatile assay read outs, measurement of cell viability/number and sorting and maintaining a homogeneous cell assay population. We show that the fluorescent signal from the GFP-FOXO fusion protein is suitable to monitor viability and it can be used to normalize the values obtained by measuring firefly luciferase activity. Furthermore, the fluorescent FOXO functions as a reporter protein for FOXO translocation and as an effector protein that drives DBE-dependent luiferase production. On the other hand the GFP-FOXO fusion protein offers the possibility to control the level of expression of the transcriptional effector in the luciferase assay, and at the same time it serves as a sorting tool to maintain a homogenous cell population. Thus, the multifunctional use of GFP-FOXO allows also to reduce the variability of the assay. The U2transLUC is an image based high throughput assay that enables compounds that produce artifacts and cytotoxicity to be identified on a single cell basis. Finally, the U2transLUC assay design might be adaptable to any transcription factor that undergoes nucleo-cytoplasmic shuttling. We challenged the U2transLUC system with chemical agents with known biological activity and were able to identify known PI3K inhibitors as double-hits that score in the translocation and the transactivation read-out. By contrast, chemical probes that inhibit the general nuclear export machinery failed to produce an increase in luciferase activity although GFP-FOXO was trapped in the cell nucleus.
In summary, our data demonstrate that U2transLUC is a sensitive and robust assay to identify small-molecule inhibitors of signaling events that regulate the subcellular localization and/or the transcriptional activity of FOXO proteins. The signaling events identified here include PI3K/Akt signaling and nuclear export. Our data raise the expectation that a more extensive chemical interrogation of the U2transLUC read-outs could lead to the identification of new molecular targets and small molecules that might contribute to the development of more potent therapeutic agents to treat tumors.
Compound supply and recombinant proteins
All chemicals were purchased from commercial sources except for the PI3K inhibitor PI-103, which was synthesized following published patent specifications. Cisplatin was provided by C. Navarro, Minerval was generously provided by P. Escriba, and all other chemicals were purchased from commercial sources: LY294002, Ratjadone A, were purchased from Calbiochem (San Diego, CA); Forskolin, Leptomycin B and Rapamycin, were purchased from LC Laboratories (Woburn, MA, U.S.A.); DMSO was purchased from Sigma-Aldrich (St. Louis, USA); Epidermal growth factor (EGF), platelet-derived growth factor (PDGF) were purchased from RELIATech A.S. (Braunschweig, Germany); and human Insulin-Like Growth Factor-I (IGF-I) and human insulin were purchased from (Roche Diagnostics, Mannheim, Germany). Stock solutions of the test compounds were deposited in three different concentrations in 96-well master plates, transferred to multiple replica plates and frozen at -80°C.
The luciferase reporter constructs pGL-1xDBE, pGL-2xDBE, pGL-3xDBE, pGL-4xDBE, pGL-5xDBE and pGL-6xDBE were generated by inserting one to six copies of the DBE consensus sequence  in front of a SV40 minimal viral promoter of the pGL3-Promoter vector (Promega). The annealed and phosphorylated oligonucleotides 5'-CTAGAAGTAAACAA-3' (1xDBE-forward) and 5'-GATCTT-GTTTAC-3' (1xDBE-reverse) or 5'-CTAGAAGTAAACAACTATGTAAACAA-3' (2xDBE-forward) and 5'-GATCTTGTTTACATAGTTGTTTACTT-3' (2xDBE-reverse) were ligated as single copy or concatemerized into NheI and BglII digested pGL3 promoter vector. In order to generate the negative control plasmid pGL-3xDBEmut, three copies of a DBE sequence that contains a point mutation that prevents FOXO binding (annealed and phosphorylated oligonucleotides (3xmDBE-forward) 5'-CTAGAAGTA-AGCAACTATGTAAG-CAACTATGTAAGCAA-3' and (3xmDBE-reverse) 5'-GAT-CTTGCTTACATAGTTGCTTACATAGTTGCT-TACATAG-3') were inserted into pGL3-Promoter vector. The constitutively active construct FOXO3a-A3, in which three PI3K-dependent phosphorylation sites have been mutated to alanine was kindly provided by Dr. M. Hu (University of Texas M. D. Anderson Cancer Center, Houston). In order to generate stable cell lines for the assay, we inserted a puromycin-resistance cassette into the pGL-3xDBE construct. This was achieved by PCR amplifying the puromycin resistance gene from pBABEpuro vector and cloning it into the SalI and BamHI sites of the pGL3-Promoter vector derived pGL-3xDBE construct, thereby obtaining pGLpuro-3xDBE.
U2-OS cells obtained from the ATCC were cultivated in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS, Sigma), antibiotics and antimycotics in a humidified incubator at 37°C with 5% CO2. U2foxRELOC cells have been described previously .
Transfection and Luciferase assays
U2OS cells were cultured in a 96-well plate (100 μl final volume per well) and transfected at 70% confluence with the plasmids indicated using the effectene transfection reagent (Qiagen). LY294002 or insulin were added individually to wells 42 hours later, at a final concentration of 20 μM or 5 mg/ml, respectively, and the cells were incubated for an additional 6 h. Luciferase assays were carried out using the Dual-Luciferase Reporter Assay System (Promega), according the manufacturer's instructions on a multilabel plate reader (Wallac Victor, Perkin-Elmer), and the ratio of firefly- to Renilla-luciferase activities was calculated. All values were presented as means ± SEM. The unpaired t-test (two-tailed) was performed for statistical analysis using the GraphPad PRISM® Version 4.0 program. Differences with a p value < 0.05 were considered statistically significant.
Generation and maintenance of U2transLUC cells
U2foxRELOC cells were transfected at 75% confluence with pGLpuro-3xDBE using the effectene transfection reagent (Qiagen). Cells were selected with puromycin (Calbiochem) for five days and the resistant colonies that best expressed the reporter constructs were then recovered and cultured, as was the most homogeneous population. Fluorescence-activated cell sorting (FACS) of GFP-FOXO expressing cells was performed on a FACSAria (BD Biosciences, San Jose, CA, USA). U2transLUC cell clones were maintained in DMEM, supplemented with 10% FBS (Sigma), antibiotics and antimycotics, 0.1 mg/ml Neomycin and 1 μg/ml puromycin. Cell cultures were maintained in a humidified incubator at 37°C with 5% CO2, and they were passaged when confluent using trypsin/EDTA.
Crystal violet assay
Triplicate samples of 104 cells were seeded in 2.5 cm dishes and allowed to attach. After 24 hours, the medium was removed and replaced with culture medium with sodium azide at the concentrations indicated, while the controls remained untreated. After the appropriate time period the cells were fixed with 0.5% glutaraldehyde and stained with 1% crystal violet. After extensive washing, crystal violet was resolubilized in 10% acetic acid and quantified at 595 nm as a relative measure of cell number.
Viability assay measuring fluorescent intensity
Samples of 104 cells per well were allowed to attach overnight in 96-well Greiner plates and the following day the culture medium was replaced with fresh medium containing the concentrations of sodium azide indicated. After a three hour treatment, the cells were washed with PBS and the fluorescent intensity was measured in a multilabel plate reader (Wallac Victor 2, Perkin-Elmer) using UV light as the excitation source, as well as a F485 CW lamp Filter and a F535 CW emission filter for 0.5 seconds per well. The values are the averages obtained from experiments carried out in triplicate.
U2transLUC cells were seeded at a density of 1.0 × 105 cells/ml in black-wall clear-bottom 96-well microplates (BD Biosciences) using a Titan Multidrop 384 automatic dispenser (Titertek Instruments, Inc., Huntsville, AL). The final volume of the cell suspension was 200 μl in each well. After incubation at 37°C in 5% CO2 for 12 hours, 2 μl of each test compound was transferred from the master plate to the assay plate. Cells were incubated in the presence of the compounds for 1 hour and the far-red fluorescent cell-permeable DNA probe, DRAQ5™ (Biostatus Ltd, Leicestershire, UK), was then added to all wells at a final concentration of 5 mM 15 minutes prior to obtaining the images. The images were acquired as described previously  using a BD Pathway™ 855 Bioimager equipped with a incubation chamber that provided a constant temperature of 37°C in 5% CO2. Images were acquired in the GFP and DRAQ5 channels using 488/10 nm EGFP excitation filter, a 515LP nm EGFP emission filter and 635/20 nm/695/55 nm DRAQ5 excitation/emission filter with a 10× dry objective. The plates were exposed for 0.066 ms (Gain 31) to acquire DAPI images and 0.55 ms (Gain 30) for GFP images. Image and data analysis was performed as described previously . After image acquisition, the plates were incubated for another 5 hours at 37°C and then the average GFP intensity per well was measured as described above. Finally, U2transLUC cells were processed to measure the firefly luciferase activity using the Luciferase Assay System (Promega) on a multilabel plate reader (Wallac Victor, Perkin-Elmer) according to the manufacturer's instructions. The relative luciferase activity, as a measurement of FOXO3a's transcriptional activity was calculated dividing the value obtained for Firefly luciferase activity for each well by the the average GFP intensity from the same well.
This work was supported by a grant from the Spanish MCyT BIO2002-00197 and the Spanish MEC (project BIO2006-02432). F. Z. is recipient of a Marie Curie Fellowship. The authors acknowledge the supply of PI-103 synthesized by R. Álvarez at the Medicinal Chemistry Department (CNIO), the expert technical assistance of E. Gonzalez and F. Blanco, and the assistance of the staff at BD Biosciences for their contribution in establishing the technology.
- Heide Van Der LP, Hoekman MF, Smidt MP: The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004, 380 (Pt 2): 297-309. 10.1042/BJ20040167.View ArticleGoogle Scholar
- Huang H, Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci. 2007, 120 (Pt 15): 2479-2487. 10.1242/jcs.001222.View ArticlePubMedGoogle Scholar
- Calnan DR, Brunet A: The FoxO code. Oncogene. 2008, 27: 2276-88. 10.1038/onc.2008.21.View ArticlePubMedGoogle Scholar
- Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA: FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007, 128: 309-23. 10.1016/j.cell.2006.12.029.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsai WC, Bhattacharyya N, Han LY, Hanover JA, Rechler MM: Insulin inhibition of transcription stimulated by the forkhead protein Foxo1 is not solely due to nuclear exclusion. Endocrinology. 2003, 144 (12): 5615-5622. 10.1210/en.2003-0481.View ArticlePubMedGoogle Scholar
- Nasrin N, Ogg S, Cahill CM, Biggs W, Nui S, Dore J, Calvo D, Shi Y, Ruvkun G, Alexander-Bridges MC: DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. Proc Natl Acad Sci USA. 2000, 97 (19): 10412-10417. 10.1073/pnas.190326997.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, Mesecar A, Adam S, Unterman TG: Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem. 2002, 277 (47): 45276-45284. 10.1074/jbc.M208063200.View ArticlePubMedGoogle Scholar
- Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A: Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci USA. 2005, 102: 11278-83. 10.1073/pnas.0502738102.PubMed CentralView ArticlePubMedGoogle Scholar
- Zanella F, Rosado A, Garcia B, Carnero A, Link W: Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem. 2008, 9: 2229-37. 10.1002/cbic.200800255.View ArticlePubMedGoogle Scholar
- Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003, 4: 463-76. 10.1016/S1535-6108(03)00303-9.View ArticlePubMedGoogle Scholar
- Schroeder FC, Kau TR, Silver PA, Clardy J: The psammaplysenes, specific inhibitors of FOXO1a nuclear export. J Nat Prod. 2005, 68: 574-6. 10.1021/np049624z.View ArticlePubMedGoogle Scholar
- Furuyama T, Nakazawa T, Nakano I, Mori N: Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J. 2000, 349: 629-34. 10.1042/0264-6021:3490629.PubMed CentralView ArticlePubMedGoogle Scholar
- Vaux DL, Whitney D, Weissman IL: Activation of physiological cell death mechanisms by a necrosis-causing agent. Microsc Res Tech. 1996, 34: 259-66. 10.1002/(SICI)1097-0029(19960615)34:3<259::AID-JEMT8>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Lizard G, Fournel S, Genestier L, Dhedin N, Chaput C, Flacher M, Mutin M, Panaye G, Revillard JP: Kinetics of plasma membrane and mitochondrial alterations in cells undergoing apoptosis. Cytometry. 1995, 21: 275-83. 10.1002/cyto.990210308.View ArticlePubMedGoogle Scholar
- Zanella F, Rosado A, Blanco F, Henderson BR, Carnero A, Link W: An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol. 2007, 5: 333-41. 10.1089/adt.2007.058.View ArticlePubMedGoogle Scholar
- Rosado A, Zanella F, Garcia B, Carnero A, Link W: A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS ONE. 2008, 3: e1823-10.1371/journal.pone.0001823.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.